China Resources Medical Holdings Co (FRA:1PH) Research & Development: €0 Mil (TTM As of Dec. 2025)


FRA:1PH China Resources Medical Holdings Co Ltd FRA:1PH
54 GF Score
Price €0.26
GF Value €0.43
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is China Resources Medical Holdings Co Research & Development?

China Resources Medical Holdings Co FRA:1PH 54 Research & Development is €0 Mil as of Dec. 2025. GuruFocus rates FRA:1PH with a GF Score™ of 54/100 and a GF Value™ of €0.43 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. China Resources Medical Holdings Co's Research & Development for the six months ended in Dec. 2025 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.

China Resources Medical Holdings Co  (FRA:1PH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

China Resources Medical Holdings Co Research & Development Related Terms

China Resources Medical Holdings Co Research & Development Historical Data

* Premium members only.

The historical data trend for China Resources Medical Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Medical Holdings Co Research & Development Chart

China Resources Medical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

China Resources Medical Holdings Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:1PH
54GF Score
China Resources Medical Holdings Co Ltd FRA:1PH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Medical Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
China Resources Medical Holdings Co (FRA:1PH) has a Research & Development of €0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on China Resources Medical Holdings Co and its competitors.
Is China Resources Medical Holdings Co's Research & Development too high?
China Resources Medical Holdings Co's current Research & Development is €0 Mil. Overall, China Resources Medical Holdings Co has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Resources Medical Holdings Co's Research & Development compare to HCA and THC?
China Resources Medical Holdings Co's Research & Development of €0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on China Resources Medical Holdings Co and its competitors. China Resources Medical Holdings Co's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Medical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Medical Holdings Co (FRA:1PH) is currently considered Possible Value Trap. The stock's GF Value™ is €0.43, compared to a current price of €0.26 — trading 38.6% below its estimated fair value. The current Research & Development is €0 Mil. China Resources Medical Holdings Co's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For China Resources Medical Holdings Co (FRA:1PH), the current Research & Development is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Medical Holdings Co (FRA:1PH) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Medical Holdings Co stock appears to be undervalued. The current stock price of €0.26 is trading 38.6% below its estimated GF Value™ of €0.43. GuruFocus considers China Resources Medical Holdings Co to be Possible Value Trap.

Key valuation signals for FRA:1PH:

  • Research & Development: €0 Mil
  • GF Value™: €0.43 vs. price of €0.26 (38.6% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the FRA:1PH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Medical Holdings Co Business Description

Other Exchanges 01515:Hong Kong
Address No. 9, Fuyi Street, 14th Floor, Kunlun Center Office Building, Fengtai District, Beijing, CHN, 100069
China Resources Medical Holdings Co Ltd is engaged in the provision of general healthcare services; provision of hospital management services, sale of pharmaceuticals, medical devices, and medical consumables, and provision of other services in the Chinese Mainland. The group has two operating segments: Hospital Business and Other Business. The Hospital Business segment includes outpatient business and inpatient business corresponding to self-owned hospitals. The Other business segment includes operation management services, supply chain services, and other ancillary services provided to participating hospitals and IOT/OT hospitals. It generates the majority of its revenue from the Hospital Business segment.
54GF Score

Get the complete analysis for FRA:1PH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price
€0.43
GF Value